The purpose of this study was to identify risk factors for recurrence of prostate adenocarcinoma after HIFU therapy. Material and methods: Material for the study was obtained from patients diagnosed with adenocarcinoma before and after HIFU treatment. Morphological study was conducted using a standard staining, and immunohistochemical markers: PCNA, Amacr, E-cadherin, Bel2, Andr, Estr, VEGF, P53, PCNA. Results: After treatment in 89% of patients with initial prostate volume greater than 50 cc the signs of recurrence of adenocarcinoma were showed. At low risk for D'Amico after treatment the expression of proliferation markers, VEGF, Amacr significantly decreased. With a high degree of risk — increased expression of Bel2. After treatment the expression of the following markers: PCNA, Amacr, VEGF significantly increased in the group of patients with the presence of invasion. Conclusion: Patients with initial prostate volume less than 50 cc, low risk to D'Amico, the lack of perineural and perivascular invasion have a low risk of recurrence after HIFU therapy; patients at high risk for D'Amico, the presence of perineural and perivascular invasion initial and prostate volume greater than 50 cc, low-grade cribriform form of adenocarcinoma have a high risk of recurrence of adenocarcinoma. Recurrence of adenocarcinoma develops independently of the period after HIFU therapy.
Popkov V.M., Maslyakova G.N., Voronin E.S., Fomkin R.N. Identification of risk factors of prostate adenocarcinoma recurrence after HIFU therapy using immunohistochemical markers // Saratov Journal of Medical Scientific Research, Vol. 10, Issue 4, 2014, pp. 654-658

The diagnostic significance of molecular markers was evaluated by immunohistochemical research of surgical and biopsy material of 106 patients with diseases of bladder and 57 patients with diseases of prostate. They received treatment at Scientific Research Institute of Fundamental and Clinical Uronephrology with monoclonal antibodies: Ki-67, PCNA, p63 (markers of proliferative activity), p53 (suppressor of tumor growth), Bcl-2, Bax (markers of apoptosis), EGFR (receptor of epidermal growth factors), PSA, PSMA, AMACR (prostate-specific antigens) and cytokeratin profile. The morphometric research was conducted on the basis of automated analysis system of digital images Ariol SL50 (Genetix)
Popkov V.M., Ponukalin A.N., Maslyakova G.N., Tsmokalyuk E.N., Bucharskaya A.B., Shirokov A.A., Burov A.M. Application of automated morphometric method of estimation of expression of immunohistochemical markers in diagnostics of prostate and bladder cancer // Saratov Journal of Medical Scientific Research, Vol. 6, Issue 4, 2010, pp. 845-849